High-level global leaders group will advocate for urgent action to combat antimicrobial resistance across all sectors and ensure the availability of important medicines for…
BV100 is being developed for the treatment of serious hospital infections caused by Carbapenem resistant Acinetobacter baumannii BioVersyshas reached a major milestone by entering clinical…
Swiss BioVersys AG has secured a CHF19m Series B financing to push clinincal development of two antiinfectives against drug-resistant pathogens. The Series B financing…
British diagnostics company FluoretiQ Ltd was selected as start-up pitch winner during the 4th annual AMR conference on 27th August. In an interview Neciah…
bye bye
As part of a large initiative to combat COVID-19 and future health pandemics WHO and EIB also joined forces on a new financing initiative…
To help guide the Global AMR R&D Hub’s collaborations a draft Collaboration Framework has been developed. Until 10th October, the consultation process is open.…
The AMR Centre Ltd has today announced a landmark agreement with the Japanese pharma company Shionogi to take forward its anti-virulence program, COT-143. The…
HHS’s Biomedical Advanced Research and Development Authority, or BARDA, will provide up to $20.7 million over 2 years to VenatoRx Pharmaceuticals as part of…
